Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) Director Dimension Capital Ii, L.P. acquired 1,111,111 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the transaction, the director owned 3,333,516 shares of the company’s stock, valued at approximately $60,003,288. This trade represents a 50.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Odyssey Therapeutics Stock Performance
Shares of NASDAQ:ODTX traded up $0.45 during trading on Tuesday, reaching $17.90. 170,745 shares of the company’s stock traded hands, compared to its average volume of 298,807. Odyssey Therapeutics, Inc. has a fifty-two week low of $15.35 and a fifty-two week high of $20.30.
Key Headlines Impacting Odyssey Therapeutics
Here are the key news stories impacting Odyssey Therapeutics this week:
- Positive Sentiment: Multiple insiders made sizable open-market purchases, including Director Nan (Ln) Li buying 1,111,111 shares, major shareholder SR One Capital Management buying 555,555 shares, and Director Shelley Chu buying 11,111 shares. Large insider buying is often viewed as a bullish sign for investors. Article Title
- Positive Sentiment: CFO Jason Haas also bought 1,000 shares, and Director Jeffrey M. Leiden purchased 5,000 shares, adding to the view that management and board members believe the stock may be undervalued. Article Title
- Neutral Sentiment: A broader healthcare IPO report noted that health-care listings raised $4.7 billion, while Odyssey and another debutante slipped. This is more of an industry backdrop than a company-specific catalyst, but it may add some pressure to newly listed biotech names. Article Title
- Negative Sentiment: One insider sale was reported from SR One Capital Management, which sold 1,780 shares. The sale is small relative to the large purchases, but it is still a modest counterpoint to the otherwise bullish insider activity. Article Title
See Also
- Five stocks we like better than Odyssey Therapeutics
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
